$ALXN Recent Headlines H-P tops SP 500; Bed Bath

New Post Public Reply Private Reply Replies (0) Message Board

Apr 10, 2014 at 12:29 PM

$ALXN Recent Headlines

H-P tops S&P 500; Bed Bath & Beyond sags on outlook 9 min ago - Saumya Vaishampayan
Tesla, Facebook, Netflix are Monday's stocks to watch 5:35 a.m. April 7, 2014 - Sue Chang
Facebook, Tesla slide into bear market territory 4:52 p.m. April 4, 2014 - Saumya Vaishampayan
Investors continue to pour out of biotech holdings 2:43 p.m. April 4, 2014 - Russ Britt
44 stocks on takeover target radar: Morgan Stanley 12:48 p.m. March 25, 2014 - blogs.marketwatch.com
U.S. stocks fall; Nasdaq skids 1.2% 4:40 p.m. March 24, 2014 - Anora Mahmudova
Apple gains on Comcast talk, new iPhone buzz 4:23 p.m. March 24, 2014 - Ben Eisen
First Solar, H-P, Symantec are stocks to watch 4:15 p.m. March 21, 2014 - Sue Chang
First Solar extends winning streak; Symantec plunges 3:06 p.m. March 21, 2014 - Ben Eisen
From every angle, technicals point to richer stocks 2:25 p.m. March 11, 2014 - The Trading Deck
U.S. stocks fall amid China worries 4:19 p.m. March 10, 2014 - Anora Mahmudova
Alexion rallies on upbeat outlook; Cliffs down on China 4:17 p.m. March 10, 2014 - Saumya Vaishampayan
Alexion bucks tide, gains on deal with France for blood disorder treatment 11:58 a.m. March 10, 2014 - blogs.marketwatch.com
Winning approval for new drugs may get harder, analyst warns 3:56 p.m. Feb. 28, 2014 - blogs.marketwatch.com
Yelp up on Yahoo deal; Apple gains as Icahn backs off 3:30 p.m. Feb. 10, 2014 - Saumya Vaishampayan
Corrective bounce, or viable market rally attempt? 11:34 a.m. Feb. 10, 2014 - Michael Ashbaugh
Utility stocks gain as Treasury yields lag 4:06 p.m. Feb. 4, 2014 - Wallace Witkowski
S&P 500 scores its best gain this year: stock market live blog recap 4:13 p.m. Jan. 30, 2014 - blogs.marketwatch.com
Facebook, Twitter highlight gainers; ADT unravels 3:55 p.m. Jan. 30, 2014 - Ben Eisen
Alexion shares leap on quarterly earnings, sunny forecast for 2014 10:56 a.m. Jan. 30, 2014 - blogs.marketwatch.com

Market Hustle: Stocks Lower Despite Better Labor Market; Nasdaq Slides 38 min ago - TheStreet.com
3 Top-Ranked Biotech Stocks on the Rebound - Analyst Blog 9:22 a.m. Today - Zacks.com
Nobody Expects a Spanish Disquistion 11:14 a.m. April 9, 2014 - Barrons.com
Alexion, Biogen Among Leading Big-Cap Biotechs 7:02 a.m. April 9, 2014 - Investors Business Daily
EPO Upholds Alnylam's McSwiggen Patent - Analyst Blog 7:00 p.m. April 8, 2014 - Zacks.com
Encouraging Pre-Clinical Data from Celldex - Analyst Blog 5:40 p.m. April 8, 2014 - Zacks.com
Intercept Pharma Prices 1M Share Offering, Shares Down - Analyst Blog 5:00 p.m. April 8, 2014 - Zacks.com
Pipeline Update from Idenix - Analyst Blog 4:55 p.m. April 8, 2014 - Zacks.com
A Sharp Pullback In Celldex Could Be A Window Of Opportunity 3:41 p.m. April 8, 2014 - Seeking Alpha
Halozyme Falls on Phase II Study Halt - Analyst Blog 12:10 p.m. April 8, 2014 - Zacks.com
Bristol-Myers Seeks FDA Approval for HCV Candidates - Analyst Blog 11:40 a.m. April 8, 2014 - Zacks.com
FDA Target Date for Gilead's HCV Candidate - Analyst Blog 11:30 a.m. April 8, 2014 - Zacks.com
RadNet Touches New 52-Week High - Analyst Blog 10:26 a.m. April 8, 2014 - Zacks.com
MannKind Slips on Afrezza Approval Delay - Analyst Blog 8:52 a.m. April 8, 2014 - Zacks.com
Idenix Pharmaceuticals (IDIX) Jumps: Stock Up 12.4% - Tale of the Tape 8:51 a.m. April 8, 2014 - Zacks.com
Puma Biotechnology (PBYI) in Focus: Stock Tumbles 18.3% - Tale of the Tape 8:45 a.m. April 8, 2014 - Zacks.com
Questcor Pharmaceuticals (QCOR) Shows Strength: Stock Surges 18.7% in Session - Tale of the Tape 8:44 a.m. April 8, 2014 - Zacks.com
Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Drugs Winner 5:00 p.m. April 7, 2014 - TheStreet.com
Momentum Slide to Continue for Netflix, Facebook? - Analyst Blog 1:21 p.m. April 7, 2014 - Zacks.com
FDA News Lifts Dyax Slightly - Analyst Blog 11:30 a.m. April 7, 2014 - Zacks.com

Alexion Pharmaceuticals to Report First Quarter 2014 Results on Thursday, April 24, 2014 10:01 a.m. Today - BusinessWire - BZX
BioMed Realty Invests In Life Science Research Facilities Leased To Yale University, Yale-New Haven Hospital And Alexion Pharmaceuticals 7:00 a.m. April 7, 2014 - PR Newswire - PRF
Study Results, Stock Price Movements, Product Launches, and Updates on Court Case Trials - Analyst Notes on Medtronic, Alexion, DaVita, Thermo Fisher Scientific, and Medicines 8:00 a.m. April 4, 2014 - PR Newswire - PRF
Drug Approvals, Stock Price Movements, and New Tools for Standardization - Analyst Notes on Biogen Idec, Alexion, Actavis, Thermo Fisher Scientific, and Medtronic 8:00 a.m. March 26, 2014 - PR Newswire - PRF
Pre-market Biotech Picks -- Research on Merrimack Pharma, Alexion Pharma, Incyte, and Aastrom Biosciences 11:25 a.m. March 25, 2014 - PR Newswire - PRF
Conference Schedules, Upcoming Marathon Applications, Revised Guidance, and Acquisitions - Analyst Notes on Celgene, Medtronic, Alexion, Quest Diagnostics, and Illumina 8:00 a.m. March 14, 2014 - PR Newswire - PRF
Alexion Revises Upward 2014 Financial Guidance for Revenues and non-GAAP EPS 6:31 a.m. March 10, 2014 - BusinessWire - BZX
Collaborations, Conferences, and Recognitions - Analyst Notes on Illumina, Alexion, Medtronic, Sirona, and NPS Pharmaceuticals 2:08 p.m. March 5, 2014 - PR Newswire - PRF
Alexion to Present at the Barclays Global Healthcare Conference 11:00 a.m. March 5, 2014 - BusinessWire - BZX
Critical Alerts For Baidu.com, Gilead Sciences, Deere, Alexion Pharmaceuticals, and Ford Released By InvestorsObserver 10:31 a.m. March 5, 2014 - PR Newswire - PRF
NICE Confirms AGNSS Positive Assessment that Eculizumab (SolirisÂ&reg

is a Very Effective Treatment for aHUS Patients and Produces Substantial Quality-Adjusted Life Year Gains of a Magnitude Rarely Seen for a New Drug 8:02 p.m. March 3, 2014 - BusinessWire - BZX
Alexion Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2014 3:01 a.m. Feb. 28, 2014 - BusinessWire - BZX
Alexion to Present at the Cowen and Company 34th Annual Health Care Conference 11:01 a.m. Feb. 25, 2014 - BusinessWire - BZX
European Commission Grants Orphan Drug Designation to SolirisÂ® (Eculizumab) for Prevention of Delayed Graft Function (DGF) after Solid Organ Transplantation 7:30 a.m. Feb. 24, 2014 - BusinessWire - BZX
Critical Alerts For Twitter, Alexion Pharmaceuticals, Pfizer, Ctrip, and AngloGold Ashanti Released By InvestorsObserver 10:31 a.m. Jan. 31, 2014 - PR Newswire - PRF
Alexion Reports Fourth Quarter and Full Year 2013 Results and Provides Financial Guidance for 2014 7:31 a.m. Jan. 30, 2014 - BusinessWire - BZX
FDA Grants Orphan Drug Designation to SolirisÂ® (eculizumab) for Prevention of Delayed Graft Function (DGF) in Renal Transplant Patients 7:30 a.m. Jan. 21, 2014 - BusinessWire - BZX
Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2013 Results on Thursday, January 30, 2014 11:00 a.m. Jan. 16, 2014 - BusinessWire - BZX
Alexion Pharmaceuticals and Moderna Therapeutics Announce Exclusive Strategic Agreement to Develop Messenger RNA Therapeuticsâ?¢ for Rare Diseases 7:30 a.m. Jan. 13, 2014 - BusinessWire - BZX
Upcoming Presentations and Stock Price Movements - Research Report on Bard, Regeneron, Alexion, Seattle Genetics, and Isis Pharmaceuticals 9:00 a.m. Jan. 9, 2014 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hyliion Class Action Deadline Nears for Investors

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

LG OLED evo W6: UAE Roadshow Starts with a Bang

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...

Voter Events by Valley Community Healthcare Aim to Empower

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

Innventure Faces Major Lawsuit Over Misleading Investors

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Masimo's smartSET™ Revolutionizes Patient Monitoring

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Weifang's Cultural Resurgence: A Global Epigraphy Fest

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

AEVEX Facing Class Action Deadline Amid Stock Turmoil

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...